Latest news with #R&D
Globe and Mail
4 hours ago
- Business
- Globe and Mail
Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance
HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that it has updated its revenue guidance for the fiscal year 2025. Guidance on R&D expenses and adjusted EBITDA remains unchanged. For the current fiscal year, the Company expects Group revenues in the range of €760-800m (previously: € 840 - 880 m; 2024: € 797.0 m); R&D expenditures are expected in a range of €40 - 50 m (unchanged; 2024: € 50.8 m); Adjusted EBITDA is expected to reach €30-50m (unchanged; 2024: € 22.6 m). The primary reasons for the refined guidance are a change in the revenue mix and significant cost savings in excess of initial targets set during the Priority Reset. Technology licensing - a key pillar of Evotec's strategic repositioning - is expected to make a stronger contribution. At the same time, the Shared R&D base business is expected to continue to operate in a challenging market environment in the second half of 2025. Group revenues were below expectations in H1 2025, while adjusted EBITDA was broadly in line with expectations. Actions are underway to transform the business towards sustainable profitable growth. - End of the ad hoc release - View the original press release on ACCESS Newswire
Associated Press
5 hours ago
- Business
- Associated Press
Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix
HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that it has updated its revenue guidance for the fiscal year 2025. R&D and adjusted EBITDA related guidance elements remain unaffected. For the current fiscal year, the Company expects revenues in the range of € 760 - 800 m (versus previously € 840 - 880 m; 2024: € 797.0 m); R&D expenditures are expected in a range of € 40 - 50 m (unchanged; 2024: € 50.8 m); Adjusted EBITDA 1 is expected to reach € 30 - 50 m (unchanged; 2024: € 22.6 m). Outlook 2028 remains unchanged with a targeted Group revenue CAGR 2024-2028 in a range of 8 - 12% and an expected adj. EBITDA margin above 20% by 2028. 1 Excluding potential costs related to the transformation program in 2025 CAGR: Compound annual growth rate In April, Evotec announced its new strategy for sustainable and profitable growth. A key element of this strategy is the refocused growth path, building on existing and new partnerships and further strengthened by leveraging its capabilities as a scalable technology and service provider. This also includes pivoting to a capex lighter model. The Company expects this value creation strategy to result in tangible results earlier than initially expected, driven by stronger than planned revenue contributions from high-margin technology license deals. After generating revenues below expectations in H1 2025, the Shared R&D base business is expected to continue to operate in a challenging market in the second half of 2025. Dr Christian Wojczewski, Chief Executive Officer of Evotec, said: 'Our strategy for sustainable and profitable growth is progressing as planned. Strong demand for higher margin businesses reflects the strength of our platforms and validates the decisions we've made around focus, partnerships, and capital efficiency. While some parts of our business continue to operate in a challenging market environment, the execution of our Priority Reset, and new strategy gives us confidence that we are well-positioned to deliver on our long-term ambitions.' The changing revenue mix is expected to positively influence the margin profile of the Evotec Group. In parallel, Evotec accelerated the implementation of its Priority Reset focused on ensuring sustainable profitable growth and right-sizing the business. The cost savings generated through these transformation efforts are now expected to exceed targets announced during the Q1 2025 results call on 06 May 2025. About Evotec SE Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. For additional information please go to and follow us on X/Twitter @Evotec and LinkedIn. Forward-looking statements This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'should,' 'target,' 'would' and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. For further information, please contact: Investor Relations Volker Braun EVP Head of Global Investor Relations & ESG [email protected] SOURCE: Evotec SE press release
Associated Press
6 hours ago
- Business
- Associated Press
Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance
HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that it has updated its revenue guidance for the fiscal year 2025. Guidance on R&D expenses and adjusted EBITDA remains unchanged. For the current fiscal year, the Company expects Group revenues in the range of €760-800m (previously: € 840 - 880 m; 2024: € 797.0 m); R&D expenditures are expected in a range of €40 - 50 m (unchanged; 2024: € 50.8 m); Adjusted EBITDA is expected to reach €30-50m (unchanged; 2024: € 22.6 m). The primary reasons for the refined guidance are a change in the revenue mix and significant cost savings in excess of initial targets set during the Priority Reset. Technology licensing - a key pillar of Evotec's strategic repositioning - is expected to make a stronger contribution. At the same time, the Shared R&D base business is expected to continue to operate in a challenging market environment in the second half of 2025. Group revenues were below expectations in H1 2025, while adjusted EBITDA was broadly in line with expectations. Actions are underway to transform the business towards sustainable profitable growth. - End of the ad hoc release - Contact: Volker Braun, EVP Head of Global Investor Relations & ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49(0)151 1940 5058 (m), [email protected] SOURCE: Evotec SE press release
Yahoo
6 hours ago
- Business
- Yahoo
Macsen Labs Achieves Breakthrough in Sodium-Ion Battery Chemistry, Files Provisional Patent, and Advances Toward Pilot-Scale Manufacturing
Video Link: UDAIPUR, India, July 21, 2025 /CNW/ -- Macsen Labs, a manufacturer of APIs, dyes, and specialty chemicals since 1952, has announced a major breakthrough in Sodium-Ion battery technology through the successful R&D-scale synthesis of its high-performance Prussian White, a next-generation cathode material for Sodium-Ion batteries. The company has filed a provisional patent for its proprietary synthesis process. The material has already undergone optimization for battery use at the company's electrochemistry and battery R&D facility and has shown promising results, driving the next phase toward pilot-scale manufacturing. "It's an interesting story, how a pharmaceutical company like ours entered the energy storage space," said Mr. Achal Agrawal, CEO of Macsen Labs and the lead researcher behind the project. "While working on Prussian Blue as a drug for radioactive poisoning, we discovered its derivative — Prussian White, which was emerging as a leading candidate for Sodium-Ion battery cathodes. That moment of curiosity led us down this path." Exactly one year ago, with zero experience in electrochemistry, Macsen's team fabricated a basic pouch cell inside a regular chemistry R&D lab, without specialized equipment. "We had no glovebox, no coater, no calendering machine, just our lab experience and synthesized material," recalled Agrawal. "When that small cell lit up an LED bulb, we knew we had something worth pursuing. That spark led us to establish a full-fledged electrochemistry lab." Today, Macsen's battery R&D facility includes an argon-filled glovebox for inert atmosphere handling, coin and pouch cell fabrication stations, electrode coaters, crimpers, vacuum dryers, and electrochemical testing systems, such as cyclers and potentiostats. With this setup, Macsen can rapidly prototype and test battery cells using its own synthesized materials, significantly reducing development time. The company already operates a pilot-scale chemical synthesis facility, which is now being used to produce Prussian White at a kilogram scale. Through numerous experiments conducted over the last year, the team has gained proficiency in Prussian White chemistry and has achieved what is likely to be one of the finest quality variants produced to date. Through its proprietary process, Macsen has achieved an energy density exceeding 150 mAh/g with Prussian White, which is comparable to Lithium Iron Phosphate (LFP). The material also shows excellent stability, fast sodium-ion mobility due to its open crystalline structure, and compatibility with existing Li-ion cell manufacturing infrastructure. "Performance-wise, it's at par with LFP, but made from abundant, low-cost materials like sodium and iron," said Agrawal. "And these elements are easily available, affordable, and free from geopolitical constraints." This project, originally incubated within Macsen Labs, is now being advanced under a dedicated entity currently under formation — 'Macsen Energy', which will focus exclusively on energy storage innovation and scale-up. "The real potential of sodium-ion batteries lies not just in electric vehicles," said Agrawal. "It lies in stationary energy storage systems that store and manage renewable energy from solar and wind. This is where India's energy transition will happen at scale." Macsen's current Sodium-Ion battery technology, using its Prussian White as cathode paired with a hard carbon anode, is well suited for applications such as battery energy storage systems (BESS) for grid and solar, household backup and inverter systems, short-range EVs, auto-rickshaws, two-wheelers, city buses, rural microgrids, and energy access solutions. The company is now focusing not only on improving cycle life, energy density, charge-discharge rates, and optimizing electrolyte-additive systems, but also on reducing the cost contribution of other components of the battery cell. Macsen aims to develop economical form factors by innovatively combining low-cost battery materials, components, and manufacturing processes, especially for large-scale stationary energy storage. One inherent cost advantage of sodium-ion technology is its use of aluminium in place of copper as the cathode current collector, which would further reduce raw material costs. To demonstrate the performance of Prussian White in commercial large-format cells, Macsen is setting up a pilot-scale cell fabrication line. The company is already sourcing equipment for this and aims to have the pilot-scale production facility operational by early 2026. "We are trying to make a new energy future for India," concluded Agrawal. "Sodium-ion batteries are India's opportunity to build a truly indigenous, scalable, and affordable energy storage ecosystem." Contactcorporate@ Video: View original content to download multimedia: SOURCE Macsen Labs Group View original content to download multimedia: Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Associated Press
6 hours ago
- Business
- Associated Press
Macsen Labs Achieves Breakthrough in Sodium-Ion Battery Chemistry, Files Provisional Patent, and Advances Toward Pilot-Scale Manufacturing
Video Link: UDAIPUR, India, July 21, 2025 /PRNewswire/ -- Macsen Labs, a manufacturer of APIs, dyes, and specialty chemicals since 1952, has announced a major breakthrough in Sodium-Ion battery technology through the successful R&D-scale synthesis of its high-performance Prussian White, a next-generation cathode material for Sodium-Ion batteries. The company has filed a provisional patent for its proprietary synthesis process. The material has already undergone optimization for battery use at the company's electrochemistry and battery R&D facility and has shown promising results, driving the next phase toward pilot-scale manufacturing. 'It's an interesting story, how a pharmaceutical company like ours entered the energy storage space,' said Mr. Achal Agrawal, CEO of Macsen Labs and the lead researcher behind the project. 'While working on Prussian Blue as a drug for radioactive poisoning, we discovered its derivative — Prussian White, which was emerging as a leading candidate for Sodium-Ion battery cathodes. That moment of curiosity led us down this path.' Exactly one year ago, with zero experience in electrochemistry, Macsen's team fabricated a basic pouch cell inside a regular chemistry R&D lab, without specialized equipment. 'We had no glovebox, no coater, no calendering machine, just our lab experience and synthesized material,' recalled Agrawal. 'When that small cell lit up an LED bulb, we knew we had something worth pursuing. That spark led us to establish a full-fledged electrochemistry lab.' Today, Macsen's battery R&D facility includes an argon-filled glovebox for inert atmosphere handling, coin and pouch cell fabrication stations, electrode coaters, crimpers, vacuum dryers, and electrochemical testing systems, such as cyclers and potentiostats. With this setup, Macsen can rapidly prototype and test battery cells using its own synthesized materials, significantly reducing development time. The company already operates a pilot-scale chemical synthesis facility, which is now being used to produce Prussian White at a kilogram scale. Through numerous experiments conducted over the last year, the team has gained proficiency in Prussian White chemistry and has achieved what is likely to be one of the finest quality variants produced to date. Through its proprietary process, Macsen has achieved an energy density exceeding 150 mAh/g with Prussian White, which is comparable to Lithium Iron Phosphate (LFP). The material also shows excellent stability, fast sodium-ion mobility due to its open crystalline structure, and compatibility with existing Li-ion cell manufacturing infrastructure. 'Performance-wise, it's at par with LFP, but made from abundant, low-cost materials like sodium and iron,' said Agrawal. 'And these elements are easily available, affordable, and free from geopolitical constraints.' This project, originally incubated within Macsen Labs, is now being advanced under a dedicated entity currently under formation — 'Macsen Energy', which will focus exclusively on energy storage innovation and scale-up. 'The real potential of sodium-ion batteries lies not just in electric vehicles,' said Agrawal. 'It lies in stationary energy storage systems that store and manage renewable energy from solar and wind. This is where India's energy transition will happen at scale.' Macsen's current Sodium-Ion battery technology, using its Prussian White as cathode paired with a hard carbon anode, is well suited for applications such as battery energy storage systems (BESS) for grid and solar, household backup and inverter systems, short-range EVs, auto-rickshaws, two-wheelers, city buses, rural microgrids, and energy access solutions. The company is now focusing not only on improving cycle life, energy density, charge-discharge rates, and optimizing electrolyte-additive systems, but also on reducing the cost contribution of other components of the battery cell. Macsen aims to develop economical form factors by innovatively combining low-cost battery materials, components, and manufacturing processes, especially for large-scale stationary energy storage. One inherent cost advantage of sodium-ion technology is its use of aluminium in place of copper as the cathode current collector, which would further reduce raw material costs. To demonstrate the performance of Prussian White in commercial large-format cells, Macsen is setting up a pilot-scale cell fabrication line. The company is already sourcing equipment for this and aims to have the pilot-scale production facility operational by early 2026. 'We are trying to make a new energy future for India,' concluded Agrawal. 'Sodium-ion batteries are India's opportunity to build a truly indigenous, scalable, and affordable energy storage ecosystem.' Contact [email protected] Video: Logo: View original content to download multimedia: SOURCE Macsen Labs Group
